Phillip Gambel

Array ( [id] => 11471255 [patent_doc_number] => 20170058038 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-02 [patent_title] => 'USE OF ANTI-CD40 ANTIBODIES FOR TREATMENT OF LUPUS NEPHRITIS' [patent_app_type] => utility [patent_app_number] => 15/252308 [patent_app_country] => US [patent_app_date] => 2016-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 17714 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15252308 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11514343 [patent_doc_number] => 20170081416 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-23 [patent_title] => 'ANTAGONIST ANTI-CD40 MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE' [patent_app_type] => utility [patent_app_number] => 15/241136 [patent_app_country] => US [patent_app_date] => 2016-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 145775 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15241136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11436115 [patent_doc_number] => 20170037136 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-09 [patent_title] => 'Anti-CD154 antibodies and methods of using them' [patent_app_type] => utility [patent_app_number] => 15/228582 [patent_app_country] => US [patent_app_date] => 2016-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 30158 [patent_no_of_claims] => 81 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15228582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11419717 [patent_doc_number] => 20170027861 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-02 [patent_title] => 'METHOD OF TREATING T CELL MEDIATED DISORDERS' [patent_app_type] => utility [patent_app_number] => 15/226652 [patent_app_country] => US [patent_app_date] => 2016-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 16129 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15226652 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11690915 [patent_doc_number] => 20170166630 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-15 [patent_title] => 'HUMANIZED ANTI-FACTOR D ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/224366 [patent_app_country] => US [patent_app_date] => 2016-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 17543 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15224366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16532162 [patent_doc_number] => 10874738 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-29 [patent_title] => Anti-CD154 antibody having improved binding, functional and safety characteristics [patent_app_type] => utility [patent_app_number] => 15/744379 [patent_app_country] => US [patent_app_date] => 2016-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 22 [patent_no_of_words] => 20033 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15744379 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16572922 [patent_doc_number] => 10894835 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-19 [patent_title] => Antibodies to CD40 with enhanced agonist activity [patent_app_type] => utility [patent_app_number] => 15/195119 [patent_app_country] => US [patent_app_date] => 2016-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 32730 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15195119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13675275 [patent_doc_number] => 20160376371 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-29 [patent_title] => ANTIBODIES TO CD40 WITH ENHANCED AGONIST ACTIVITY [patent_app_type] => utility [patent_app_number] => 15/195098 [patent_app_country] => US [patent_app_date] => 2016-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41463 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15195098 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12750589 [patent_doc_number] => 20180142030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-24 [patent_title] => ANTIBODIES TO CD40 [patent_app_type] => utility [patent_app_number] => 15/579450 [patent_app_country] => US [patent_app_date] => 2016-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40614 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15579450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12832204 [patent_doc_number] => 20180169240 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-21 [patent_title] => METHODS OF TREATING AUTOIMMUNE AND ALLOIMMUNE DISORDERS [patent_app_type] => utility [patent_app_number] => 15/739622 [patent_app_country] => US [patent_app_date] => 2016-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18618 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15739622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16549762 [patent_doc_number] => 10882911 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-05 [patent_title] => CD40L binding polypeptide [patent_app_type] => utility [patent_app_number] => 15/739560 [patent_app_country] => US [patent_app_date] => 2016-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 7 [patent_no_of_words] => 12443 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15739560 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11408971 [patent_doc_number] => 09556263 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-31 [patent_title] => 'Methods for treating atypical hemolytic uremic syndrome with high concentration formulations of anti-C5 antibodies' [patent_app_type] => utility [patent_app_number] => 15/176774 [patent_app_country] => US [patent_app_date] => 2016-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 42682 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15176774 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11067711 [patent_doc_number] => 20160264676 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-15 [patent_title] => 'ANTI-CD26 ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/169386 [patent_app_country] => US [patent_app_date] => 2016-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 34278 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15169386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11311740 [patent_doc_number] => 20160347850 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-01 [patent_title] => 'ANTI-CD40 ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/167598 [patent_app_country] => US [patent_app_date] => 2016-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 53734 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15167598 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11205167 [patent_doc_number] => 09434784 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2016-09-06 [patent_title] => 'Nucleic acids encodng anti-C5A antibodies' [patent_app_type] => utility [patent_app_number] => 15/161893 [patent_app_country] => US [patent_app_date] => 2016-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 58980 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15161893 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11054471 [patent_doc_number] => 20160251433 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-01 [patent_title] => 'ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS' [patent_app_type] => utility [patent_app_number] => 15/160364 [patent_app_country] => US [patent_app_date] => 2016-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 46732 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15160364 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11290505 [patent_doc_number] => 20160340437 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-24 [patent_title] => 'Methods for Managing Sepsis' [patent_app_type] => utility [patent_app_number] => 15/159297 [patent_app_country] => US [patent_app_date] => 2016-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 10890 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15159297 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11311737 [patent_doc_number] => 20160347847 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-01 [patent_title] => 'Anti-OX40 Antibodies and Methods of Use Thereof' [patent_app_type] => utility [patent_app_number] => 15/148720 [patent_app_country] => US [patent_app_date] => 2016-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 45 [patent_no_of_words] => 90105 [patent_no_of_claims] => 49 [patent_no_of_ind_claims] => 22 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15148720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11555219 [patent_doc_number] => 20170101465 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-13 [patent_title] => 'Use of TNFalpha Antibody for Treatment of Hidradenitis Suppurativa (HS)' [patent_app_type] => utility [patent_app_number] => 15/148089 [patent_app_country] => US [patent_app_date] => 2016-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 38411 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 21 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15148089 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13519513 [patent_doc_number] => 20180311299 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => EFFICACY OF AN ANTI-C5 ANTIBODY IN THE PREVENTION OF ANTIBODY MEDIATED REJECTION IN SENSITIZED RECIPIENTS OF A KIDNEY TRANSPLANT [patent_app_type] => utility [patent_app_number] => 15/569338 [patent_app_country] => US [patent_app_date] => 2016-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27129 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15569338 [rel_patent_id] =>[rel_patent_doc_number] =>)